This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Johnson & Johnson (
JNJ) is having a stellar year in 2013. Shares of the healthcare giant have rallied more than 27% since the start of the year, around double what the venerable S&P 500 has managed to accomplish over the same time period. Johnson's set to announce its earnings numbers tomorrow.
Johnson & Johnson is the prototypical blue-chip stock. The $252 billion firm pays out just shy of a 3% dividend yield, and it's got a model that works well in good times and in bad ones. The business includes everything from consumer products such as Band-Aid brand bandages to pharmaceuticals and medical devices.
While pharma makes up a large chunk of the firm's net income, the consumer and medical device segments offer investors diversification that few big pharma names can match -- especially as patent drop-offs plague valuations in the industry.
JNJ is a big beneficiary of changing demographics. As the baby boomer population in the developed world gets older, medical costs are expected to inflate in kind, and that's a good thing for pharma-driven firms such as Johnson & Johnson. Elsewhere, burgeoning younger populations in emerging markets are there to pick up the demand for its consumer products.